# **Resource Summary Report**

Generated by NIF on May 3, 2025

# **Alzheimer's Research Forum**

RRID:SCR\_006416 Type: Tool

### **Proper Citation**

Alzheimer's Research Forum (RRID:SCR\_006416)

### **Resource Information**

URL: http://www.alzforum.org/

Proper Citation: Alzheimer's Research Forum (RRID:SCR\_006416)

**Description:** A community building portal dedicated to understanding Alzheimer's disease and related disorders, it reports on the latest scientific findings from basic research to clinical trials, creates and maintains public databases of essential research data and reagents, and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across disciplines.

Abbreviations: ALZForum, ARF

**Resource Type:** disease-related portal, portal, topical portal, community building portal, narrative resource, discussion, data or information resource

**Keywords:** alzheimer's disease, human, mouse, community building portal, forum, FASEB list

Related Condition: Alzheimer's disease

Funding: grants ; individual donations

Availability: Free, Acknowledgement requested

Resource Name: Alzheimer's Research Forum

Resource ID: SCR\_006416

Alternate IDs: nif-0000-00095

License URLs: http://www.alzforum.org/terms-of-use

**Record Creation Time:** 20220129T080236+0000

Record Last Update: 20250503T055823+0000

#### **Ratings and Alerts**

No rating or validation information has been found for Alzheimer's Research Forum.

No alerts have been found for Alzheimer's Research Forum.

#### Data and Source Information

Source: <u>SciCrunch Registry</u>

## **Usage and Citation Metrics**

We found 106 mentions in open access literature.

Listed below are recent publications. The full list is available at <u>NIF</u>.

Hao M, et al. (2025) Nanomaterials-mediated lysosomal regulation: a robust proteinclearance approach for the treatment of Alzheimer's disease. Neural regeneration research, 20(2), 424.

Chen J, et al. (2024) Amyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease. Aging and disease, 15(1), 201.

Singh H, et al. (2024) New insights into the therapeutic approaches for the treatment of tauopathies. Neural regeneration research, 19(5), 1020.

Batista AF, et al. (2024) The Importance of Complement-Mediated Immune Signaling in Alzheimer's Disease Pathogenesis. International journal of molecular sciences, 25(2).

Area-Gomez E, et al. (2024) Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis. Journal of Alzheimer's disease : JAD, 98(4), 1243.

Chu D, et al. (2024) Tau truncation in the pathogenesis of Alzheimer's disease: a narrative review. Neural regeneration research, 19(6), 1221.

de Boni L, et al. (2024) Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson's patients. EMBO molecular medicine, 16(7), 1657.

Rizzi L, et al. (2024) Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting. Acta neuropathologica communications, 12(1), 36.

Gilani N, et al. (2024) Homozygous TREM2 c.549del; p.(Leu184Serfs\*5) variant causing Nasu-Hakola disease in three siblings in a consanguineous Iraqi family: Case report and review of literature. Molecular genetics & genomic medicine, 12(6), e2476.

Stellick Bedrejo CA, et al. (2024) Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer's Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated. PloS one, 19(9), e0307761.

Chu J, et al. (2024) Biomaterials-based anti-inflammatory treatment strategies for Alzheimer's disease. Neural regeneration research, 19(1), 100.

Zhang Y, et al. (2024) E674Q (Shanghai APP mutant), a novel amyloid precursor protein mutation, in familial late-onset Alzheimer's disease. Genes & diseases, 11(2), 1022.

Arber C, et al. (2024) The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated A?43 and atypical clinical manifestations. Alzheimer's & dementia : the journal of the Alzheimer's Association, 20(7), 4717.

Cummings J, et al. (2023) Lecanemab: Appropriate Use Recommendations. The journal of prevention of Alzheimer's disease, 10(3), 362.

Yu HJ, et al. (2023) Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study. EBioMedicine, 94, 104665.

Hata S, et al. (2023) Brain p3-Alc? peptide restores neuronal viability impaired by Alzheimer's amyloid ?-peptide. EMBO molecular medicine, 15(5), e17052.

Zhang Y, et al. (2023) Amyloid ?-based therapy for Alzheimer's disease: challenges, successes and future. Signal transduction and targeted therapy, 8(1), 248.

Quan M, et al. (2023) Shared and unique effects of ApoE?4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer's disease. Alzheimer's research & therapy, 15(1), 40.

Visconte C, et al. (2023) Plasma microglial-derived extracellular vesicles are increased in frail patients with Mild Cognitive Impairment and exert a neurotoxic effect. GeroScience, 45(3), 1557.

Zhang B, et al. (2023) Design of the formalized and integrated Alzheimer's Disease Ontology and its application in retrieving textual data via text mining. Database : the journal of biological databases and curation, 2023.